CombiMatrix to Apply for Transfer of Shares to Nasdaq Capital Market | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CombiMatrix said after the close of the market Thursday that its board of directors has authorized management of the firm to voluntarily apply to have its stock transferred to the Nasdaq Capital Market from the Nasdaq Global Market.

The firm has decided to take this action rather than submit a plan to the exchange to regain compliance with Nasdaq Global Market listing requirements.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.